These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
43. Discovery of riociguat (BAY 63-2521): a potent, oral stimulator of soluble guanylate cyclase for the treatment of pulmonary hypertension. Mittendorf J; Weigand S; Alonso-Alija C; Bischoff E; Feurer A; Gerisch M; Kern A; Knorr A; Lang D; Muenter K; Radtke M; Schirok H; Schlemmer KH; Stahl E; Straub A; Wunder F; Stasch JP ChemMedChem; 2009 May; 4(5):853-65. PubMed ID: 19263460 [TBL] [Abstract][Full Text] [Related]
44. A Hopeful Prospect of Riociguat as a Soluble Guanylate Cyclase Stimulator for Management of Pressure Ulcers. Azadi S; Ashrafi H; Azadi A Curr Drug Discov Technol; 2018; 15(1):20-23. PubMed ID: 28914189 [TBL] [Abstract][Full Text] [Related]
45. First acute haemodynamic study of soluble guanylate cyclase stimulator riociguat in pulmonary hypertension. Grimminger F; Weimann G; Frey R; Voswinckel R; Thamm M; Bölkow D; Weissmann N; Mück W; Unger S; Wensing G; Schermuly RT; Ghofrani HA Eur Respir J; 2009 Apr; 33(4):785-92. PubMed ID: 19129292 [TBL] [Abstract][Full Text] [Related]
46. Clinical Pharmacokinetic and Pharmacodynamic Profile of Riociguat. Frey R; Becker C; Saleh S; Unger S; van der Mey D; Mück W Clin Pharmacokinet; 2018 Jun; 57(6):647-661. PubMed ID: 29086344 [TBL] [Abstract][Full Text] [Related]
47. Phosphodiesterase type 5 inhibitor to riociguat transition is associated with hemodynamic and symptomatic improvement in pulmonary hypertension. Davey R; Benza RL; Murali S; Raina A Pulm Circ; 2017; 7(2):539-542. PubMed ID: 28597779 [TBL] [Abstract][Full Text] [Related]
48. Nitric oxide-independent stimulation of soluble guanylate cyclase with BAY 41-2272 in cardiovascular disease. Boerrigter G; Burnett JC Cardiovasc Drug Rev; 2007; 25(1):30-45. PubMed ID: 17445086 [TBL] [Abstract][Full Text] [Related]
49. [Optimization of specific therapy for pulmonary hypertension: the possibilities of riociguat]. Martynyuk TV; Shmalts AA; Gorbachevsky SV; Chazova IE Ter Arkh; 2021 Sep; 93(9):1117-1124. PubMed ID: 36286873 [TBL] [Abstract][Full Text] [Related]
52. Early Observations on the Use of Riociguat in a Large, Metropolitan Pulmonary Arterial Hypertension/Chronic Thromboembolic Pulmonary Hypertension Treatment Center. Sulica R; Fenton R; Cefali F Cardiol Ther; 2015 Dec; 4(2):209-18. PubMed ID: 26411969 [TBL] [Abstract][Full Text] [Related]
53. Pulmonary Arterial Hypertension: Pathophysiology and Treatment. Lan NSH; Massam BD; Kulkarni SS; Lang CC Diseases; 2018 May; 6(2):. PubMed ID: 29772649 [TBL] [Abstract][Full Text] [Related]
55. [Pulmonary hypertension : What is new in therapy?]. Sommer N; Hecker M; Tello K; Richter M; Liebetrau C; Weigand MA; Seeger W; Ghofrani A; Gall H Anaesthesist; 2016 Aug; 65(8):635-52. PubMed ID: 27492004 [TBL] [Abstract][Full Text] [Related]
56. Phosphodiesterase-3 inhibition prevents the increase in pulmonary vascular resistance following inhaled nitric oxide withdrawal in lambs. Thelitz S; Oishi P; Sanchez LS; Bekker JM; Ovadia B; Johengen MJ; Black SM; Fineman JR Pediatr Crit Care Med; 2004 May; 5(3):234-9. PubMed ID: 15115560 [TBL] [Abstract][Full Text] [Related]
57. Analysis of the nitric oxide-cyclic guanosine monophosphate pathway in experimental liver cirrhosis suggests phosphodiesterase-5 as potential target to treat portal hypertension. Schaffner D; Lazaro A; Deibert P; Hasselblatt P; Stoll P; Fauth L; Baumstark MW; Merfort I; Schmitt-Graeff A; Kreisel W World J Gastroenterol; 2018 Oct; 24(38):4356-4368. PubMed ID: 30344420 [TBL] [Abstract][Full Text] [Related]
58. Expression and activity of soluble guanylate cyclase in injury and repair of anti-thy1 glomerulonephritis. Peters H; Wang Y; Loof T; Martini S; Kron S; Krämer S; Neumayer HH Kidney Int; 2004 Dec; 66(6):2224-36. PubMed ID: 15569311 [TBL] [Abstract][Full Text] [Related]
59. Identification of downstream target genes regulated by the nitric oxide-soluble guanylate cyclase-cyclic guanosine monophosphate signal pathway in pulmonary hypertension. Zou L; Xu X; Zhai Z; Yang T; Jin J; Xiao F; Wang C J Int Med Res; 2016 Jun; 44(3):508-19. PubMed ID: 27048385 [TBL] [Abstract][Full Text] [Related]
60. [Phosphodiesterase-5 inhibitors for the treatment of pulmonary arterial hypertension]. Beltrán-Gámez ME; Sandoval-Zárate J; Pulido T Arch Cardiol Mex; 2015; 85(3):215-24. PubMed ID: 26047999 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]